by Eric Christianson | Jan 12, 2025 | Endocrine Medication and Disease State Clinical Pearls
Treating patients with type II diabetes often requires an array of medications to control blood sugar and manage various comorbidities. Understanding possible drug-drug and drug-disease interactions between medications is extremely important for optimizing medication...
by Eric Christianson | Jan 5, 2025 | Gastrointestinal Medication and Disease State Clinical Pearls
I’ve had some wonderful guest posts in the past and I couldn’t help but notice this awesome post on LinkedIn from a fellow pharmacist! April Oliveros is the author of this quick hitter on “Does Every Patient On Anticoagulation Need a PPI?” You...
by Eric Christianson | Dec 29, 2024 | Endocrine Medication and Disease State Clinical Pearls
Reducing diabetes medications in geriatric patients with low A1c involves careful consideration of the risks and benefits of continued intensive glycemic control. In older adults, particularly those with multiple comorbidities, frailty, or limited life expectancy,...
by Eric Christianson | Dec 8, 2024 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
Fosfomycin is an antibiotic (discovered in 1969) that has been making a resurgence in popularity in the last few years due to its activity against both gram-positive and gram-negative bacteria. Currently, it is a treatment option for women with uncomplicated urinary...
by Eric Christianson | Nov 27, 2024 | Renal, Urology, and Electrolytes Medication and Disease State Clinical Pearls
Methenamine is a medication used for urinary tract infection (UTI) prophylaxis, however, it is not considered a traditional antibiotic. It works by acidifying the urine and essentially making it sterile by killing off existing bacteria in the urinary tract and...
by Eric Christianson | Nov 24, 2024 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
Insulin icodec may have a new competitor in the near future. Insulin efsitora is another once-weekly insulin currently undergoing phase 3 clinical trials, with Lilly’s 3rd phase being termed the QWINT trials (Once Weekly (QW) Insulin Therapy (INT)). These trials are...
